In lymphomas, PIK3CA has been reported to be amplified in 15/22 (68%) cases of mantle cell lymphoma (MCL) [8], 9/161 (5.6%) cases of chronic lymphocytic leukemia (CLL) [9], and mutated in 1/76 (1.3%) cases of DLBCL [10]; while PIK3CD has been reported to be mutated in 3/73 (4.1%) cases of DLBCL [11]. Here, PIK3CA is linked to lymphoma.